Biopharma

Sino Biological

Sino Biological is an internationally recognized reagent supplier and contract research organization. Sino Biological's core technology platform is its in-house developed mammalian cell-based recombinant expression system. The system employs a range of proprietary reagents and processes, enabling high-efficient production of antigens and antibodies. The current catalog includes 10,000+ recombinant antigens, along with 2,000+ unique clones of monoclonal antibodies.

Sino Biological is dedicated to supporting SARS-COV-2 research. The company’s antibodies and antigens have been widely used to manufacture rapid antigen and antibody tests. Many of them have received the EUA from the FDA.

Wyss Institute for Biologically Inspired Engineering at Harvard University

This animation explains how Wyss Institute researchers and their industry partners aim to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain. Credit: Wyss Institute at Harvard University. Learn more at: https://wyss.harvard.edu/collaboration/brain-targeting-program/

Wyss Institute Brain Targeting Program

Teach Me in 10

For this installment of Teach Me in 10, we're bringing you a cross over event with our sister publication, Analytical Cannabis. Much of what we know about the cannabis plant and its effects on the human body has only been formally discovered in the past 60 years. A good deal of these pioneering investigations have involved today's Teach Me in 10 guest: [url][link]https://www.abdn.ac.uk/ims/profiles/rgp[/link][name]Roger Pertwee[/name][/url], an emeritus professor at the University of Aberdeen. Join this Teach Me in 10 session to hear Professor Pertwee discuss how cannabis chemicals interact with the body’s own cannabinoid receptors, why such natural and synthetic cannabinoids show potential therapeutic benefits and how they might be stabilized for future clinical trials. We hope you enjoy this cross over event! You can learn more about the cannabis research field by visiting [url][link]https://www.analyticalcannabis.com/[/link][name]Analytical Cannabis[/name][/url], a leading publication for scientists, technicians, and business professionals working in the cannabis, hemp, and psychedelics industries.

Potential Therapeutic Uses of Cannabinoids With Professor Roger Pertwee

Custom Videos from Technology Networks

Watch this video to learn more about the custom and bulk antibody services offered by Bethyl Labs/Fortis Life Sciences.

Custom and Bulk Antibody Services

Creative Proteomics videos

PTMs refer to the covalent and generally enzymatic modification of proteins during or after protein biosynthesis. It denotes changes in the polypeptide chain as a result of adding distinct chemical moieties to amino acid residues. PTMs are the foundation of governing intricate cellular process, such as cell division, growth, differentiation, signaling and regulation. Also, PTMs are involved in many cellular processes including the maintenance of protein structure and integrity, regulation of metabolism & defense processes, cellular recognition and morphology alternation. Consequently, analysis of protein post-translational modifications, including the modification categories and modified sites, is particularly crucial for the study of cell biology and disease diagnostics and prevention.

With years’ experience in advanced experiment equipment, Creative Proteomics can provide a variety of PTM services to assist your scientific research. https://www.creative-proteomics.com/services/protein-post-translational-modification-analysis.htm

Introduction of PTM

Creative Enzymes

Enzyme labeling, also known as immunoenzymatic technology, is based on the immune reaction. It uses a highly specific immune reaction combined with the efficient catalytic action of enzymes to form a complete set of biological technologies that are highly specific and highly sensitive. https://www.creative-enzymes.com/service/Enzyme-Labelling-Services_358.html

Enzyme Labelling - Creative Enzymes

Mutant library

In stem cell research, there is a challenging but necessary step to validate cells throughout the whole experiments, which is dependent on tools and strategies to distinguish stem cells from a heterogeneous cellular population. Specifically, cellular, molecular, and functional assay tools are required for stem cell characterization.

https://www.creative-bioarray.com/services/stem-cell-research.htm

Stem Cell Research

Sekisui XenoTech

Presenter: Brian Ogilvie, Ph.D, Vice President of Scientific Consulting at SEKISUI XenoTech

Abstract:
Although cytochrome P450 (CYP)-mediated metabolism continues to be of major importance for a large proportion of small molecule new drug candidates, various methods in recent decades have accelerated the development of drug candidates with significant non CYP-mediated metabolism. Increased interest in these molecules stems from the efforts to develop drug candidates possibly lacking CYP metabolism liability from the drug interactions and toxicity standpoints. Regulatory agencies still have a safety interest in understanding the biochemical pathways involved in the metabolism of these drugs.

In general, uridine diphosphate glucuronosyltransferases (UGTs) are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Reaction phenotyping of many of these enzymes is not as straightforward as with CYPs due to their inherent diversity and limited research tools available. With UGTs, commercially available recombinant human preparations are available for the most relevant enzymes, although selective inhibitors may be lacking. In the case of aldehyde oxidase, a recombinant human enzyme and relatively selective inhibitors are available. For hydrolases, carbonyl reductases and other enzymes such as FMO, strategies may rely on the use of various subcellular fractions, plasma, and inhibitors to elucidate a plurality of the enzymes that may contribute to drug metabolism. The complexity of elucidation of non CYP-mediated metabolism is reflected in regulatory safety requirements.

In this webinar, Dr. Brian Ogilvie will discuss strategies to address non-CYP related metabolism questions in your drug’s safety assessment and following the presentation, he will answer follow up questions from the audience.

Key concepts discussed in this webinar will include:
 - In vitro approaches to evaluate non-CYP enzyme contribution to new drug candidates
 - Case examples

Request a copy of the slides: https://www.xenotech.com/about/events/webinar-an-overview-of-non-cyp-mediated-metabolism-pathways-and-in-vitro-evaluation-strategies/
Questions, comments and requests: https://www.xenotech.com/contact/
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenter:
Dr. Brian Ogilvie currently serves as Vice President of Scientific Consulting at SEKISUI XenoTech. Brian obtained his Ph.D. in toxicology from the University of Kansas Medical Center and B.A. in molecular biology from William Jewell College. He joined XenoTech in 1997. From 1999 to 2006 Dr. Ogilvie was the head of the CYP Inhibition Department at SEKISUI XenoTech. Brian is an author or coauthor on over 50 scientific posters, peer-reviewed publications and book chapters on the topics of drug metabolism, transport and drug-drug interactions, and has represented the company as an invited speaker at various drug metabolism conferences. In April 2006, Brian became a member of the SEKISUI XenoTech Consulting Department, in which he participates in drug-drug interaction-related R&D projects and authoring various publications, and also writes expert opinions for consulting clients. As Vice President of Scientific Consulting, Dr. Ogilvie is additionally involved in quality management and strategic planning for the company in scientifically relevant areas.

An Overview of Non CYP Mediated Metabolism Pathways and In Vitro Evaluation Strategies

SiliCycle Inc.

E-PAK is a family of radial flow purification cartridges developed specifically for pharmaceutical processing.

Offered with a choice of metal scavengers, bare silica & activated carbons, these cartridges are designed to remove precious metal catalysts, reaction-by-products or color from synthetic reaction mixtures and natural products.

For more information on E-PAK, visit us at:
https://www.silicycle.com/products/e-pak-purification-cartridges

Biopharma

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.